Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$66.02 USD

66.02
10,225,804

-2.91 (-4.22%)

Updated Sep 5, 2024 04:00 PM ET

After-Market: $66.02 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Edwards Lifesciences (EW) Down 3.3% Since Earnings Report: Can It Rebound?

Edwards Lifesciences (EW) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

    LabCorp Grows on Solid Diagnostics, Currency Woes a Drag

    Although LabCorp's (LH) Covance drug development business puts up a dull performance, the market is upbeat about its Diagnostics business, which has recently displayed a solid show.

      Henry Schein's Merritt Buyout to Boost U.S. Veterinary Arm

      Henry Schein's (HSIC) acquisition of Merritt Veterinary supplies will brace its existing U.S. animal health business, particularly in the southeastern United States.

        LabCorp & Interpace Extend Deal, Boost Cancer Portfolio

        LabCorp's (LH) agreement to offer Interpace Diagnostics' molecular tests, ThyGenX and ThyraMIR gets renewed and extended for another two years.

          C. R. Bard's (BCR) LUTONIX 035 Gets FDA Pre-Market Approval

          The early market acceptance of the LUTONIX platform has been impressive and C. R. Bard (BCR) is likely to witness an expanded adoption of this technology as the market continues to mature.

            Hill-Rom (HRC) Stock Down With Dull Patient Support Systems

            Hill-Rom's (HRC) Patient Support Systems revenue decreases due to the adverse effect of the WatchChild and Architectural Products divestitures along with lower rental revenues.

              LabCorp's $1.2 Billion Chiltern Buyout Gets FTC Approval

              The Federal Trade Commission (FTC) has granted LabCorp's (LH) request for an early closure of Chiltern's acquisition under HSR Act.

                Chemed (CHE) on Growth Track With VITAS & Roto-Rooter Arms

                The raised outlook for both Roto-Rooter unit and the bottom line indicate Chemed's (CHE) estimate of improved operating results in the upcoming quarters.

                  Align Technology-Patterson Dental Deal Expands iTero Reach

                  Align Technology (ALGN) progresses with a slew of developments in the scanners and services segment.

                    LabCorp to Add ChromaDex's Arm, Inorganic Expansion On Track

                    LabCorp's (LH) decision to buy the analytical testing services arm of ChromaDex should fortify its Covance Food Solutions business.

                      Thermo Fisher's Patheon Buyout Gains Antitrust Clearance

                      Thermo Fisher (TMO) gets antitrust clearance to move a step closer toward completion of Patheon acquisition.

                        Kevin Cook headshot

                        Bull of the Day: Edwards Lifesciences (EW)

                        The world leader in non-surgical heart valve replacement keeps the "beat and raise" going with innovation and execution

                          Here's Why Investors Should Buy Amedisys (AMED) Right Now

                          Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business.

                            Align Technology's Invisalign Sales Strong Amid Margin Woes

                            Align Technology's (ALGN) huge InvisAlign prospects in North America and international regions render optimism. However, escalating costs and expenses put pressure on the company's margins.

                              LabCorp Partners OmniSeq to Grow in Immuno-Oncology Space

                              LabCorp (LH) decides to distribute OmniSeq's molecular diagnostics assays in the United States and beyond to grow in immuno-oncology space.

                                CVS Health (CVS) Releases Encouraging Flu Shot Survey Data

                                CVS Health's (CVS) survey on flu vaccination came up with positive outcome. The data confirms untapped opportunities in the flu vaccine market.

                                  Here's Why Investors Should Buy BioTelemetry (BEAT) Now

                                  BioTelemetry's (BEAT) buyout of LifeWatch AG has expanded its product portfolio and customer base in the cardiac monitoring and diagnostic services space.

                                    Zacks.com featured highlights: SP Plus Corp, Edwards Lifesciences, Magna International and NVIDIA

                                    Zacks.com featured highlights: SP Plus Corp, Edwards Lifesciences, Magna International and NVIDIA

                                      Stryker (SYK) to Gain From Solid Portfolio and Acquisitions

                                      Stryker's (SYK) diverse product portfolio alongside acquisition-driven strategy would continue to boost growth prospects. However, competition in the Chinese market raise concern.

                                        Tirthankar Chakraborty headshot

                                        4 Stocks to Buy as Q2 Earnings Season Nears Close

                                        Earnings growth is considered to be the most significant variable in influencing the share price.

                                          Accelerate Diagnostics (AXDX) In Focus: Stock Rises 5.1%

                                          Accelerate Diagnostics (AXDX) was a big mover last session, as the company saw its shares rise more than 5% on the day.

                                            Fluidigm (FLDM) Licenses CFTR Assay From Baylor Genetics

                                            Fluidigm (FLDM) has licensed rights to commercialize the cystic fibrosis transmembrane conductance regulator. The company is focused on improving its Juno automated microfluidic system.

                                              Allscripts, Elligo Health Enter in Strategic Partnership

                                              Allscripts' (MDRX) Strategic Partnership with Elligo Health would aid the company in capturing the Clinical Research Organizations' lucrative market.

                                                Walgreens' (WBA) Research Website to Add Value in Healthcare

                                                Walgreens Boots Alliance's (WBA) Center for Health & Wellbeing Research is set to improve patient care and outcomes while reducing health care costs at the same time.

                                                  Omnicell Upgrades Web Portal, Grows in Medication Management

                                                  Omnicell (OMCL) makes progress in medicare adherence with four new enhancements to its web portal PMAP.